Moxifloxacin, however, does not show pharmacokinetic interaction with theophylline or warfarin. Dosage adjustments are not required in patients with renal impairment or in patients with mild to moderate hepatic insufficiency.
The potential for photosensitivity reactions during moxifloxacin treatment is low. Drugs Jan; Fluoroquinolone treatment of skin and skin structure infections.
Drugs ; 58 Suppl. Combating bacterial resistance in skin and skin-structure infection: Am J Ther Jan; 6: Moxifloxacin Avelox prescribing information. National Committee for Clinical Laboratory Standards. Methods for antimicrobial testing of anaerobic bacteria, 4th ed. Performance standards for antimicrobial susceptibility testing, 8th informational supplement.
Method for dilution antimicrobial susceptibility for bacteria that grow aerobically, 4th ed. Methods for antimicrobial testing of anaerobic bacteria, 3rd ed. Performance standards for antimicrobial susceptibility testing, informational supplement. In vitro activities of sitafloxacin DUa and six other fluoroquinolones against 8, clinical bacterial isolates. This drug may make you dizzy.
Do not drive, use machinery, or do any activity that requires alertness until you are sure you can perform such activities safely. This medication may make you more sensitive to the sun. Limit your time in the sun. Avoid tanning booths and sunlamps. Use sunscreen and wear protective clothing when outdoors. Moxifloxacin may cause live bacterial vaccines such as typhoid vaccine to not work as well. Approved Acetyldigoxin may decrease the cardiotoxic activities of Moxifloxacin.
Experimental Alfuzosin may increase the QTc-prolonging activities of Moxifloxacin. Approved Moxifloxacin may increase the QTc-prolonging activities of Amiodarone. Approved Amoxapine may increase the QTc-prolonging activities of Moxifloxacin.
Approved Moxifloxacin may increase the QTc-prolonging activities of Anagrelide. Approved Apomorphine may increase the QTc-prolonging activities of Moxifloxacin. Approved, Investigational Moxifloxacin may increase the QTc-prolonging activities of Arsenic trioxide.
Approved Moxifloxacin may increase the QTc-prolonging activities of Asenapine. Approved Atazanavir may increase the QTc-prolonging activities of Moxifloxacin.
Approved Azithromycin may increase the QTc-prolonging activities of Moxifloxacin. Approved The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Moxifloxacin. Investigational Moxifloxacin may increase the QTc-prolonging activities of Bedaquiline.
Approved Bevacizumab may increase the cardiotoxic activities of Moxifloxacin. Approved The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Moxifloxacin. Approved Moxifloxacin may increase the QTc-prolonging activities of Ceritinib. Approved Moxifloxacin may increase the QTc-prolonging activities of Chloroquine.
Approved Moxifloxacin may increase the QTc-prolonging activities of Clarithromycin. Approved Clomipramine may increase the QTc-prolonging activities of Moxifloxacin.
Approved Moxifloxacin may increase the QTc-prolonging activities of Crizotinib. Approved Cyclophosphamide may increase the cardiotoxic activities of Moxifloxacin. Approved, Investigational Cymarin may decrease the cardiotoxic activities of Moxifloxacin. Experimental Dabrafenib may increase the QTc-prolonging activities of Moxifloxacin. Approved Dasatinib may increase the QTc-prolonging activities of Moxifloxacin.
Approved Desflurane may increase the QTc-prolonging activities of Moxifloxacin. Approved Desipramine may increase the QTc-prolonging activities of Moxifloxacin. Approved Deslanoside may decrease the cardiotoxic activities of Moxifloxacin. Approved Digitoxin may decrease the cardiotoxic activities of Moxifloxacin. Approved, Investigational Digoxin may decrease the cardiotoxic activities of Moxifloxacin.
Approved Diphenhydramine may increase the QTc-prolonging activities of Moxifloxacin. Approved Moxifloxacin may increase the QTc-prolonging activities of Disopyramide.
Approved The risk or severity of adverse effects can be increased when Docetaxel is combined with Moxifloxacin.
Approved Moxifloxacin may increase the QTc-prolonging activities of Dolasetron. While taking moxifloxacin, avoid excessive sunlight or artificial ultraviolet light exposure e. Stop taking the medication and contact your doctor if sun sensitivity occurs. Moxifloxacin may increase the chance of tendon injury. Injury occurs more commonly for seniors who are also taking corticosteroid medications.
If there is any new pain in the tendons or joints, stop taking moxifloxacin, avoid physical exercise, and consult your doctor. This medication should not be used during pregnancy unless the benefits outweigh the risks. If you become pregnant while taking this medication, stop taking it immediately and contact your doctor. It is not known if moxifloxacin passes into breast milk.
If you are a breast-feeding mother and are taking this medication, it may affect your baby. Talk to your doctor about whether you should continue breast-feeding.
The safety and effectiveness of this medication have not been established for children under 18 years of age. What other drugs could interact with this medication?
Tags: diazepam 2.5mg rectal gel prozac and mood disorders trileptal average price norco california prison inmate search
© Copyright 2017 Moxifloxacin 400mg - mso-sport.ru.